Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma

Molecular and Cellular Endocrinology

Volumn 364, Issue 1-2, 2012, Pages 101-104

  Doghman, Mabrouka ^a   Lalli, Enzo ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Adrenal; Cancer; Pharmacology; Signalling

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; EVEROLIMUS; FR 180204; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NVP AEW 541; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMIDAZOLES; MICE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDAZINES; QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867539766     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.08.014     Document Type: Article

References (11)

1. Barlaskar F., Spalding A.C., Heaton J.H., Kuick R., Kim A.C., Thomas D.G., Giordano T.J., Ben-Josef E., Hammer G.D. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2009, 94:204-212.
2. Cho D.C., Cohen M.B., Panka D.J., Collins M., Ghebremichael M., Atkins M.B., Signoretti S., Mier J.W. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 2010, 16:3628-3638.
3. Doghman M., Cazareth J., Lalli E. The Tcf/β catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J. Clin. Endocrinol. Metab. 2008, 93:3222-3225.
4. Doghman M., El Wakil A., Cardinaud B., Thomas E., Wang J., Zhao W., Peralta Del Valle M.H.C., Figueiredo B.C., Zambetti G.P., Lalli E. Regulation of Insulin-like growth factor - mammalian target of rapamycin signalling by microRNA in childhood adrenocortical tumors. Cancer Res. 2010, 70:4666-4675.
5. Fassnacht M., Libé R., Kroiss M., Allolio B. Adrenocortical carcinoma: a clinician's update. Nat. Rev. Endocrinol. 2011, 7:323-335.
6. Fassnacht M., Terzolo M., Allolio B., Baudin E., Haak H., Berruti A., Welin S., Schade-Brittinger C., Lacroix A., Jarzab B., Sorbye H., Torpy D.J., Stepan V., Schteingart D.E., Arlt W., Kroiss M., Leboulleux S., Sperone P., Sundin A., Hermsen I., Hahner S., Willenberg H.S., Tabarin A., Quinkler M., de la Fouchardière C., Schlumberger M., Mantero F., Weismann D., Beuschlein F., Gelderblom H., Wilmink H., Sender M., Edgerly M., Kenn W., Fojo T., Müller H.H., Skogseid B. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 2012, 366:2189-2197. FIRM-ACT Study Group.
7. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chène P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., García-Echeverría C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7:1851-1863.
8. Manara M.C., Nicoletti G., Zambelli D., Ventura S., Guerzoni C., Landuzzi L., Lollini P.L., Maira S.M., García-Echeverría C., Mercuri M., Picci P., Scotlandi K. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin. Cancer Res. 2010, 6:530-540.
9. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res. 2006, 66:1500-1508.
10. Roccaro A.M., Sacco A., Husu E.N., Pitsillides C., Vesole S., Azab A.K., Azab F., Melhem M., Ngo H.T., Quang P., Maiso P., Runnels J., Liang M.C., Wong K.K., Lin C., Ghobrial I.M. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenström macroglobulinemia. Blood 2010, 115:559-569.
11. Roper J., Richardson M.P., Wang W.V., Richard L.G., Chen W., Coffee E.M., Sinnamon M.J., Lee L., Chen P.C., Bronson R.T., Martin E.S., Hung K.E. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 2011, 6:e25132.